EGFR and glioblastoma: Consequently, a number of preclinical and clinical studies revealed that GBM can be induced and maintained by aberrant EGFR and Ras/RAF/ERK-signaling networks, also capable of revealing important downstream factors including Akt or mTORC1 signaling, associated with a benefit from the EGFR-targeting antibody nimotuzumab [29].